TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 991548
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of isoprenaline after acupuncture
Study: 30953540
Drug: Tofacitinib (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tofacitinib (5 mg and 10 mg BID)
Study: 28114147
Drug: Feedback group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Feedback group receiving activity and sleep data at each dialysis treatment
Study: 26431646
Drug: Traditional Chinese
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese medicine granules combined with conventional treatment (oxygen uptake, nebulization, anti-infection)
Study: 26431646
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (oxygen uptake, nebulization, anti-infection)
Study: 23603206
Drug: Reduced nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced nicotine content (RNC) cigarettes with 21 mg nicotine patch
Study: 21438804
Drug: Dabigatran etexilate
Normalized name: Dabigatran etexilate
DrugBank: Dabigatran etexilate (DB06695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dabigatran etexilate 110 mg twice daily
Study: 9513822
Drug: Omeprazole 40
Normalized name: omeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 40 mg bid + Amoxycillin 0.5 g qid
Study: 9513822
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg bid + Amoxycillin 0.5 g qid
Study: 27374467
Drug: High-dose melphalan
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose melphalan (200 mg/m2) and salvage ASCT
Study: 27374467
Drug: Weekly oral
Normalized name: elagolix
DrugBank: Elagolix (DB11979)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly oral cyclophosphamide (400 mg/m2 per week for 12 weeks)
Study: 27374467
Drug: High-dose melphalan
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose melphalan and salvage ASCT
Study: 27374467
Drug: Weekly oral
Normalized name: elagolix
DrugBank: Elagolix (DB11979)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly oral cyclophosphamide
Study: 24679060
Drug: Intensive medical
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive medical therapy plus Roux-en-Y gastric bypass
Study: 24679060
Drug: Intensive medical
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive medical therapy plus sleeve gastrectomy
Study: 17611340
Drug: Quadruple fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadruple fluid aerosol inhalation before radiotherapy
Study: 17611340
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (conventional oral care)
Study: 7599918
Drug: Caffeine 2.1
Normalized name: caffeine 2.17 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine 2.1 mg*kg‐1 body weight
Study: 7599918
Drug: Caffeine 4.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine 4.3 mg*kg‐1 body weight
Study: 7599918
Drug: Caffeine 8.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine 8.6 mg*kg‐1 body weight
Study: 31504798
Drug: Active screening
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active screening group (annual invitation for low-dose computed tomography for 4 years)
Study: 21890090
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ischemia and VT
Study: 15927929
Drug: Tomatoes cooked
Normalized name: Tomato
DrugBank: Tomato (DB10573)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tomatoes cooked with olive oil (25 ml); 470 g per meal for 5 days
Study: 15927929
Drug: Tomatoes cooked
Normalized name: Tomato
DrugBank: Tomato (DB10573)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tomatoes cooked without olive oil; 470 g per meal for 5 days
Study: 10333123
Drug: Combined diphtheria-tetanus-acellular
Normalized name: acellular pertussis vaccine, inactivated / diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Boostrix]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio virus vaccine
Study: 10333123
Drug: Hiberix, ActHib,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hiberix, ActHib, Pedvax, HibTITER (Hib conjugate vaccines)
Study: 8949976
Drug: Long-term therapy
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term therapy to improve glucose control
Study: 1754753
Drug: Pivampicillin 700
Normalized name: pivampicillin
DrugBank: Pivampicillin (DB01604)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pivampicillin 700 mg twice daily for 7 days
Study: 31222796
Drug: Chlorzoxazone 500
Normalized name: chlorzoxazone 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorzoxazone 500 mg
Study: 31222796
Drug: Chlorzoxazone microdose
Normalized name: Chlorzoxazone
DrugBank: Chlorzoxazone (DB00356)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlorzoxazone microdose (0.05-500 mg)
Study: 31222796
Drug: Chlorzoxazone microdose
Normalized name: Chlorzoxazone
DrugBank: Chlorzoxazone (DB00356)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlorzoxazone microdose (≥50 mg)
Study: 27539026
Drug: Reading on
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reading on a self-luminous tablet
Study: 17650790
Drug: Guben Yiliu
Normalized name: MENTHOL 3 g TRANSDERMAL PATCH [TIANHE GUBEN YAOSHEN TIE GAO]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guben Yiliu II (GY II) combined with arterial perfusion with chemotherapeutic agent
Study: 17650790
Drug: Chemotherapeutic agent
Normalized name: Other chemotherapeutics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapeutic agent alone
Study: 7866915
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g of oral calcium
Study: 7866915
Drug: 200 IU
Normalized name: Vitamin E 200 IU Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 IU of intranasal calcitonin
Study: 7866915
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (control session)
Study: 2547245
Drug: Oral ciprofloxacin
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ciprofloxacin for three months in addition to conventional local therapy (N=18)
Study: 2547245
Drug: Conventional local
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional local therapy (Control group, N=8)
Study: 28053158
Drug: Bioengineered bilayered
Normalized name: acellular tissue engineered vessel Drug Implant [Symvess]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bioengineered bilayered living cellular construct (BLCC) skin substitute together with standard of care (compression therapy)
Study: 28053158
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care (compression therapy)
Study: 21457668
Drug: Oral alpha-lipoic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral alpha-lipoic acid (ALA) 1200 mg/day for 8 weeks
Study: 21457668
Drug: Placebo 1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 1200 mg/day for 8 weeks
Study: 16517331
Drug: Group P
Normalized name: High mobility group protein HMGI-C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group P - preoperative placebo tablet, propofol induction, propofol-air/O2 maintenance
Study: 16517331
Drug: Group I
Normalized name: Platelet group IIa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group I + O - preoperative 8-mg ondansetron tablet, thiopental induction, isoflurane-N2O maintenance
Study: 16517331
Drug: Group I
Normalized name: Platelet group IIa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group I (control) - preoperative placebo tablet, thiopental induction, isoflurane-N2O maintenance
Study: 8888927
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (delaying physiotherapy until abnormal physical signs became apparent)
Study: 30896976
Drug: Involved R/L
Approvals — FDA: no, EMA: no, PMDA: no
Description: Involved R/L IKDC‐SKF
Study: 30896976
Drug: R/L IKDC‐SKF
Approvals — FDA: no, EMA: no, PMDA: no
Description: R/L IKDC‐SKF
Study: 27485060
Drug: Rowachol 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rowachol 100 mg orally three times daily for 3 months after surgery
Study: 21680781
Drug: Quercetin 500
Normalized name: quercetin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quercetin 500 mg once a day for 13 days
Study: 19301734
Drug: Sequential boost
Normalized name: BOOST
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential boost (15 Gy/5F)
Study: 17461530
Drug: 40mL of
Normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40mL of 300mg ropivacaine with 1:200,000 epinephrine and 5mg morphine
Study: 15200445
Drug: Sildenafil citrate
Normalized name: Sildenafil Citrate
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sildenafil citrate 50 mg administered 2 hours before hemodialysis
Study: 15200445
Drug: Sildenafil citrate
Normalized name: Sildenafil Citrate
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sildenafil citrate 50 mg administered 2 hours after hemodialysis
Study: 12473004
Drug: Cilostazol 50
Normalized name: cilostazol 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilostazol 50 mg bid or 100 mg bid for 12, 16, or 24 weeks
Study: 11440349
Drug: Tiagabine (TGB),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiagabine (TGB), dosage up to 64 mg/day
Study: 9402169
Drug: Cisplatin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin (50 mg/m2), Epirubicin (70 mg/m2), Paclitaxel (175 mg/m2 over three hours)
Study: 8500917
Drug: ITF 282
Approvals — FDA: no, EMA: no, PMDA: no
Description: ITF 282 (60 mg iron once daily for children ≤40 kg; twice daily for children >40 kg)
Study: 8500917
Drug: Ferrous polystyrene
Normalized name: polystyrene sulfonate
DrugBank: Tolevamer (DB01344)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ferrous polystyrene sulphonate (52.5 mg iron once daily for children ≤40 kg; twice daily for children >40 kg)
Study: 3319629
Drug: Exercise training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise training plus individual relaxation and breathing therapy (treatment A)
Study: 28090293
Drug: Oral treprostinil
Normalized name: Treprostinil
DrugBank: Treprostinil (DB00374)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral treprostinil (up-titrated from 0.25 mg twice daily)
Study: 20450357
Drug: mod SLA
Normalized name: slash pine pollen extract
DrugBank: Pinus elliottii pollen (DB10747)
Approvals — FDA: no, EMA: no, PMDA: no
Description: mod SLA implants
Study: 16189077
Drug: Single 2.0-g
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 2.0-g oral dose of azithromycin microspheres (n = 213)
Study: 16189077
Drug: 7-day regimen
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 7-day regimen of levofloxacin (500 mg/day) (n = 214)
Study: 12549813
Drug: Telephone contact
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telephone contact and physician's letter combination
Study: 12549813
Drug: In-person counseling
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In-person counseling and physician's letter combination
Study: 10381107
Drug: Calcium mupirocin
Normalized name: Mupirocin Calcium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium mupirocin ointment
Study: 8873694
Drug: Isosorbide (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isosorbide (20 mg by mouth t.i.d.)
Study: 8873694
Drug: Nicardipine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicardipine (20 mg by mouth t.i.d.)
Study: 1998848
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg stanozolol intramuscularly 24 hours before operation, followed by 5 mg stanozolol orally twice daily for 6 weeks
Study: 1998848
Drug: Placebo intramuscularly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo intramuscularly 24 hours before operation, followed by placebo orally twice daily for 6 weeks
Study: 27316679
Drug: Yirui capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yirui capsule
Study: 24733515
Drug: Stepped collaborative
Normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Stepped collaborative care intervention including motivational interviewing, medication, and cognitive behavioral therapy targeting PTSD and depressive symptoms.
Study: 16782910
Drug: PCV chemotherapy
Normalized name: PCV
DrugBank: Penciclovir (DB00299)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PCV chemotherapy plus radiotherapy (RT), n = 147
Study: 14567804
Drug: Triptorelin depot
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triptorelin depot 11.25 mg 3 months before surgery (group A)
Study: 9096431
Drug: Tamoxifen (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen (40 mg/day) for 1 month
Study: 25360652
Drug: Ulinastatin (intravenous)
Normalized name: ulinastatin
DrugBank: Ulinastatin (DB12038)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ulinastatin (intravenous)
Study: 11961025
Drug: Continue triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continue triple drug therapy (Control)
Study: 7553634
Drug: 2B1 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2B1 at 1.0 mg/m2
Study: 7553634
Drug: 2B1 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2B1 at 2.5 mg/m2
Study: 7553634
Drug: 2B1 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2B1 at 5.0 mg/m2
Study: 7553634
Drug: 2B1 (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2B1 (all doses)
Study: 2183632
Drug: Intravenous caffeine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous caffeine pretreatment
Study: 2183632
Drug: Electrical stimulus
Normalized name: Limulus polyphemus extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electrical stimulus intensity dosing
Study: 7392905
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg of Dexedrine per 70 kg of body weight
Study: 31372757
Drug: Transdermal estradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal estradiol (100 mcg/day)
Study: 21747085
Drug: Edrecolomab (five
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edrecolomab (five infusions at 28-day intervals)
Study: 21747085
Drug: Observation without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Observation without adjuvant therapy
Study: 19267710
Drug: New insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: New insulin treatment (group III, n = 245)
Study: 19267710
Drug: Insulin before
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin before inclusion continued during the first year of follow up (group IV, n = 271)
Study: 17114657
Drug: Etoposide 100
Normalized name: etoposide 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etoposide 100 mg/m2 on days 1-3 and cisplatin 80 mg/m2 on day 1 with concurrent twice-daily thoracic radiotherapy (TRT) (1.5 Gy per fraction, total dose of 45 Gy) followed by irinotecan 60 mg/m2 on days 1, 8, and 15 and cisplatin 60 mg/m2 on day 1 of a 4-week cycle
Study: 14618645
Drug: Budesonide or
Normalized name: budesonide Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide or Nedocromil (anti-inflammatory therapy)
Study: 8796410
Drug: i.v. bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. bolus of 1 g/kg of 25% albumin over 4 h, repeated after 24 and 48 h
Study: 8796410
Drug: Continuous 24-h
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous 24-h infusion of 1 g/kg of 25% albumin throughout the 60-h study period
Study: 1320259
Drug: ORG 2766
Normalized name: ORG-34517
DrugBank: ORG-34517 (DB05423)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ORG 2766 (20 mg, 4 capsules daily for six weeks)
Study: 1320259
Drug: Placebo (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (4 capsules daily for six weeks)
Study: 3881948
Drug: Aztreonam 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aztreonam 0.5 to 1 g twice daily
Study: 3881948
Drug: Aztreonam 1
Normalized name: aztreonam 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aztreonam 1 g three times daily
Study: 3881948
Drug: Cefamandole 1
Normalized name: cefamandole 1 g injectable powder for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefamandole 1 g three times daily
Study: 3881948
Drug: Aztreonam 1
Normalized name: aztreonam 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aztreonam 1 to 6 g per day for eight days
Study: 27456983
Drug: Protease inhibitor
Normalized name: Protease inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protease inhibitor monotherapy (80% darunavir, 14% lopinavir, 6% other)
Study: 28495562
Drug: Protease inhibitor
Normalized name: Protease inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protease inhibitor monotherapy
Study: 22310542
Drug: Transmitted drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transmitted drug resistance mutations
Study: 20178875
Drug: Western medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medicine (WM) - Terazosin Hydrochloride Hytrin (THH)
Study: 20178875
Drug: Traditional Chinese
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese medicine (TCM) - herbal Saxifrage tablet (HST)
Study: 20178875
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (WM and TCM)
Study: 15251662
Drug: Levothyroxine (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levothyroxine (1.5 to 2.0 mg/kg of body weight daily)
Study: 7734104
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg ICR
Study: 7734104
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg ICR
Study: 7734104
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg ICR
Study: 7734104
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg ICR
Study: 2390689
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of 5 FU
Study: 2390689
Drug: Intraperitoneal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraperitoneal administration of 5 FU
Study: 31987536
Drug: Phyllanthus amarus
Normalized name: Phyllanthus amarus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phyllanthus amarus nanoparticle gel applied by phonophoresis (PP)
Study: 31987536
Drug: Ultrasound therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound therapy (UT)
Study: 31469816
Drug: Nivolumab plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab plus ipilimumab (first-line treatment)
Study: 31469816
Drug: Nivolumab (second-line
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab (second-line treatment)
Study: 28492860
Drug: Anti-VEGF treatment
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Anti-VEGF treatment prior to study participation
Study: 22717102
Drug: OPRM1 genotype
Normalized name: PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 8
DrugBank: Streptococcus pneumoniae type 8 capsular polysaccharide antigen (DB10326)
Approvals — FDA: no, EMA: no, PMDA: no
Description: OPRM1 genotype (G allele presence) among non-Hispanic whites
Study: 22717102
Drug: OPRM1 genotype
Normalized name: PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 8
DrugBank: Streptococcus pneumoniae type 8 capsular polysaccharide antigen (DB10326)
Approvals — FDA: no, EMA: no, PMDA: no
Description: OPRM1 genotype (G allele presence) among Hispanics
Study: 22717102
Drug: OPRM1 genotype
Normalized name: PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 8
DrugBank: Streptococcus pneumoniae type 8 capsular polysaccharide antigen (DB10326)
Approvals — FDA: no, EMA: no, PMDA: no
Description: OPRM1 genotype (G allele presence) among African Americans
Study: 15488105
Drug: Randomized treatment
Normalized name: jojoba oil, randomized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomized treatment efficacy trials
Study: 7812072
Drug: 800 mg/day
Normalized name: RibaTab 800 mg/day Compliance Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg/day Calcium supplements (two different forms)
Study: 7812072
Drug: Calcium supplements
Normalized name: CALCIUM SUPPLEMENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplements (in fractured patients)
Study: 2338120
Drug: Diclofenac hydroxyethylpyrrolidine
Normalized name: diclofenac hydroxyethylpyrrolidine 1.292 % Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac hydroxyethylpyrrolidine (DIEP) 2 X 50 mg
Study: 2338120
Drug: Diclofenac sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac sodium 2 X 50 mg
Study: 28975429
Drug: Intra-oral cooling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-oral cooling device
Study: 23639862
Drug: Bowman Birk
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bowman Birk Inhibitor Concentrate (BBIC)
Study: 20693809
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy + infliximab
Study: 19805692
Drug: Oral satraplatin
Normalized name: satraplatin
DrugBank: Satraplatin (DB04996)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral satraplatin (80 mg/m² on days 1 to 5 of a 35-day cycle) and prednisone (5 mg twice daily)
Study: 19805692
Drug: Placebo and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo and prednisone (5 mg twice daily)
Study: 15875093
Drug: Risedronate (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risedronate (5 mg/daily)
Study: 10192656
Drug: Oestrogen replacement
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oestrogen replacement therapy (2 mg of 17-beta-oestradiol orally for 3 months)